CYP3A4 is responsible for the metabolism of over 50% of the most widely administered BC therapeutic agents including cyclophosphamide, docetaxel, doxorubicin and paclitaxel; most of which are utilised in New Zealand clinics52. The gene discussed is CYP3A4; the disease is breast cancer.